- Strategic combination to acquire Castle Creek Biosciences, bringing Phase 3 rare disease candidate D-Fi.
- Upfront issuance of 5.2M Pelthos common shares (~32.5% fully diluted) plus up to 5.8M shares and $300M in milestones.
- Transaction expected to close in Q1 2027.
?? Positive AI Sentiment (+3.0 / 10)